Depletion of proBNP1-108 in patients with heart failure prevents cross-reactivity with natriuretic peptides.
BACKGROUND: After synthesis by cardiomyocytes, precursor proBNP1-108 is cleaved into NT-proBNP and BNP. Recently, cross-reactivity between these assays was discussed. The aim of this study was to characterize the cross-reactivities, through a new biochemical innovative approach consisting in the tot...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2013-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC3775813?pdf=render |
| _version_ | 1818897202586583040 |
|---|---|
| author | François Roubille Delphine Delseny Jean-Paul Cristol Delphine Merle Nicolas Salvetat Catherine Larue Jean-Marc Davy Florence Leclercq Jean-Luc Pasquie Luc Guerrier Jeannette Fareh Anne-Marie Dupuy |
| author_facet | François Roubille Delphine Delseny Jean-Paul Cristol Delphine Merle Nicolas Salvetat Catherine Larue Jean-Marc Davy Florence Leclercq Jean-Luc Pasquie Luc Guerrier Jeannette Fareh Anne-Marie Dupuy |
| author_sort | François Roubille |
| collection | DOAJ |
| description | BACKGROUND: After synthesis by cardiomyocytes, precursor proBNP1-108 is cleaved into NT-proBNP and BNP. Recently, cross-reactivity between these assays was discussed. The aim of this study was to characterize the cross-reactivities, through a new biochemical innovative approach consisting in the total depletion of the circulating proBNP1-108 in patients with heart failure (HF). METHODS: This prospective study included 180 patients with chronic HF. BNP and NT-proBNP were dosed with commercial kits. ProBNP1-108 was determined using an ELISA research assay specific to the precursor. ProBNP1-108 depletion was performed by immunocapture with a specific antibody targeting exclusively the ProBNP1-108 hinge region. ProBNP1-108, BNP and NT-proBNP levels were determined before and after depletion using this process in HF patients. RESULTS: Mean age was 74.34 +/-12.5 y, and 69% of patients were males. NYHA classes II and III were the most frequent (32% and 45% respectively). Before depletion, ProBNP1-108, NT-proBNP and BNP levels were 316.8+/-265.9 pg/ml; 6,054.0+/-11,539 pg/ml and 684.3+/-82.1 pg/ml respectively, and were closely correlated with NHYA classes. After immuno-depletion, proBNP1-108 was decreased in mean by 96% (p<0.0001), BNP by 53% (p<0.0001) and NT-proBNP by 5%. The relationship between BNP or NT-proBNP and NHYA classes remained unchanged. CONCLUSION: Current BNP and NT-proBNP assays measured as well proBNP molecule. This cross reactivity percentage has been controversial. Thanks to the removal of circulating proBNP1-108 with our immunodepletion process, we are now able to assess the remaining "true" BNP and NT-proBNP molecules and further evaluate their clinical relevance. |
| first_indexed | 2024-12-19T19:12:26Z |
| format | Article |
| id | doaj.art-f0ce60ab679445ddb7f3c94a8df78ab9 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-19T19:12:26Z |
| publishDate | 2013-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-f0ce60ab679445ddb7f3c94a8df78ab92022-12-21T20:09:15ZengPublic Library of Science (PLoS)PLoS ONE1932-62032013-01-0189e7517410.1371/journal.pone.0075174Depletion of proBNP1-108 in patients with heart failure prevents cross-reactivity with natriuretic peptides.François RoubilleDelphine DelsenyJean-Paul CristolDelphine MerleNicolas SalvetatCatherine LarueJean-Marc DavyFlorence LeclercqJean-Luc PasquieLuc GuerrierJeannette FarehAnne-Marie DupuyBACKGROUND: After synthesis by cardiomyocytes, precursor proBNP1-108 is cleaved into NT-proBNP and BNP. Recently, cross-reactivity between these assays was discussed. The aim of this study was to characterize the cross-reactivities, through a new biochemical innovative approach consisting in the total depletion of the circulating proBNP1-108 in patients with heart failure (HF). METHODS: This prospective study included 180 patients with chronic HF. BNP and NT-proBNP were dosed with commercial kits. ProBNP1-108 was determined using an ELISA research assay specific to the precursor. ProBNP1-108 depletion was performed by immunocapture with a specific antibody targeting exclusively the ProBNP1-108 hinge region. ProBNP1-108, BNP and NT-proBNP levels were determined before and after depletion using this process in HF patients. RESULTS: Mean age was 74.34 +/-12.5 y, and 69% of patients were males. NYHA classes II and III were the most frequent (32% and 45% respectively). Before depletion, ProBNP1-108, NT-proBNP and BNP levels were 316.8+/-265.9 pg/ml; 6,054.0+/-11,539 pg/ml and 684.3+/-82.1 pg/ml respectively, and were closely correlated with NHYA classes. After immuno-depletion, proBNP1-108 was decreased in mean by 96% (p<0.0001), BNP by 53% (p<0.0001) and NT-proBNP by 5%. The relationship between BNP or NT-proBNP and NHYA classes remained unchanged. CONCLUSION: Current BNP and NT-proBNP assays measured as well proBNP molecule. This cross reactivity percentage has been controversial. Thanks to the removal of circulating proBNP1-108 with our immunodepletion process, we are now able to assess the remaining "true" BNP and NT-proBNP molecules and further evaluate their clinical relevance.http://europepmc.org/articles/PMC3775813?pdf=render |
| spellingShingle | François Roubille Delphine Delseny Jean-Paul Cristol Delphine Merle Nicolas Salvetat Catherine Larue Jean-Marc Davy Florence Leclercq Jean-Luc Pasquie Luc Guerrier Jeannette Fareh Anne-Marie Dupuy Depletion of proBNP1-108 in patients with heart failure prevents cross-reactivity with natriuretic peptides. PLoS ONE |
| title | Depletion of proBNP1-108 in patients with heart failure prevents cross-reactivity with natriuretic peptides. |
| title_full | Depletion of proBNP1-108 in patients with heart failure prevents cross-reactivity with natriuretic peptides. |
| title_fullStr | Depletion of proBNP1-108 in patients with heart failure prevents cross-reactivity with natriuretic peptides. |
| title_full_unstemmed | Depletion of proBNP1-108 in patients with heart failure prevents cross-reactivity with natriuretic peptides. |
| title_short | Depletion of proBNP1-108 in patients with heart failure prevents cross-reactivity with natriuretic peptides. |
| title_sort | depletion of probnp1 108 in patients with heart failure prevents cross reactivity with natriuretic peptides |
| url | http://europepmc.org/articles/PMC3775813?pdf=render |
| work_keys_str_mv | AT francoisroubille depletionofprobnp1108inpatientswithheartfailurepreventscrossreactivitywithnatriureticpeptides AT delphinedelseny depletionofprobnp1108inpatientswithheartfailurepreventscrossreactivitywithnatriureticpeptides AT jeanpaulcristol depletionofprobnp1108inpatientswithheartfailurepreventscrossreactivitywithnatriureticpeptides AT delphinemerle depletionofprobnp1108inpatientswithheartfailurepreventscrossreactivitywithnatriureticpeptides AT nicolassalvetat depletionofprobnp1108inpatientswithheartfailurepreventscrossreactivitywithnatriureticpeptides AT catherinelarue depletionofprobnp1108inpatientswithheartfailurepreventscrossreactivitywithnatriureticpeptides AT jeanmarcdavy depletionofprobnp1108inpatientswithheartfailurepreventscrossreactivitywithnatriureticpeptides AT florenceleclercq depletionofprobnp1108inpatientswithheartfailurepreventscrossreactivitywithnatriureticpeptides AT jeanlucpasquie depletionofprobnp1108inpatientswithheartfailurepreventscrossreactivitywithnatriureticpeptides AT lucguerrier depletionofprobnp1108inpatientswithheartfailurepreventscrossreactivitywithnatriureticpeptides AT jeannettefareh depletionofprobnp1108inpatientswithheartfailurepreventscrossreactivitywithnatriureticpeptides AT annemariedupuy depletionofprobnp1108inpatientswithheartfailurepreventscrossreactivitywithnatriureticpeptides |